PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “Blood Coagulation Disorders”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 19 recordsLinked to original sources
PubMed2002

[Role of newly developed technology in blood coagulation disorders].

Clarification of blood coagulation disorders has been made progress based on newly developed technologies. ANTITHROMBIN III: In 1979, studies were carried out on antithrombin III(AT III) as a blood coagulation inhibitor from the first Japanese case of congenital AT III deficiency found in the laboratory sample. An alternative anticoagulant to maintain fluidity in extracorporeal circuit in an AT III deficient patient requiring hemodialysis was needed. In 1989, it was firstly introduced argatroban, a synthetic thrombin inhibitor as an alternative anticoagulant instead of human antithrombin III concentrate plus heparin regimen during hemodialysis. In 1992, success of good delivery in pregnant woman with an AT III deficiency was obtained to maintain normal level of AT III by the concentrates. DYSFIBRINOGENEMIA: Two families of congenital dysfibrinogenemia in clue to abnormally high levels of serum fibrinogen degradation products(FDP) were found. Polymerization detect due to dysfibrinogenemia induced high level of serum FDP and normal level of fibrin d-dimer products. HEPARIN COFACTOR II DEFICIENCY: A patient with congenital heparin cofactor II(HCII) deficiency was found in clue to four episodes of repeated restenosis under heparin-anticoagulated coronary angioplasty. For preventing the restenosis, argatroban as an alternative of heparin was used during coronary angioplasty. No restenosis after the angioplasty was appeared in anticoagulation with argatroban. Genetic analysis of the HCII was described that gene protein is secreted normally, but rapidly degraded in the circulation. FACTOR VII: In Japanese elderly, increase of Factor VII clotting activity was found to relate to high risk of cardiovascular disease. Elevation of activated FVII(FVIIa) as an activation marker of FVII in cardiovascular disease indicates to be an independent risk factor for cardiovascular disease. HEPARIN INDUCED THROMBOCYTOPENIA: HIT: HIT is believed to be less frequent in Japanese because of lack of recognition due to poor understanding of HIT's paradox. A survey in Japanese indicated to be no less frequent compared with that of the West. A causativity for HIT has been identified as antibodies against PF4/heparin complexes. As detection of the antibodies can easily be done by ELISA test, the test is desirable to become popular. Treatment for HIT is recommended to stop heparin and start a thrombin inhibitor. In Japan, argatroban and nafamostat mesilate are selected as an alternative agent for HIT, but both drugs have no approval for Japanese HIT patients.

Adult↗
PubMed1983

[Blood coagulation disorder during the combined treatment of testicular tumor patients].

The mechanism of hemocoagulation before, during and after combined therapy was studied in 47 cases of testicular tumor. Thrombophilia was suggested by the basal level of hemocoagulation. All patients received a course of combined therapy which included surgery, telegammatherapy and polychemotherapy. In the course of treatment, all patients revealed a decrease in the coagulative properties of blood which manifested itself in hemorrhages in 7 cases. After therapy, blood coagulation indexes did not vary much from normal. This is believed by the authors to be an indication of the efficacy of the treatment.

Adolescent↗
PubMedDate not supplied

[Blood coagulation disorders in infants with infectious gastroenteritis].

The study included 28 infants with infectious gastroenteritis who evolved with disturbances of coagulation and in whom laboratory tests were practiced by micromethods through capillary puncture. The most frequently seen abnormality was a combination of vitamin K dependent factors deficiency with thrombocytopenia. Another observation in our study is that hypofibrinogenemia in infants with infectious gastroenteritis is not always secondary to disseminated intravascular coagulation. A decrease in fibrinogen in these cases is explained by a lack in synthesis of this factor in infants with malnutrition since out of 16 malnourished infants, 75% evolved with hypofibrinogenemia, while eutrophic infants evolved with normal fibrinogen. The disseminated intravascular coagulation syndrome was seen more frequently in patients with infectious gastroenteritis complicated with septicemia and shock, 57% of the patients did not show manifestations of bleeding nor of thrombosis which justifies in these cases a systematic investigation of the coagulation mechanism.

Blood Coagulation Disorders↗
PubMed1980

[Blood coagulation disorders in liver cirrhosis in relation to the degree of portal hypertension].

Investigated were the haemostasis of 45 patients with histologically confirmed liver cirrhosis. The patients were subdivided into three groups according to the extent of their porto caval collateral circulation as proved by laparoscopy, gastroscopy and radiology: I = no porto caval shunts (n = 10); II = moderate porto caval shunts (n = 13); III = distinct porto caval shunts (n = 14). A 4th group consisted of 8 patients with bleeding from oesophageal varices. The results indicated a significant decrease in the stages I-III of the coagulation factors produced in the liver (incl. factor XIII and AT III) and the thrombocytes. Unchanged remained the concentration of factor VIII, whereas the factor VIII associated antigen showed an increased activity depending on the severity of the disease (stages I-III). In patients with bleeding from oesophageal varices, values of about 300% of normal could be demonstrated. Depending on the stage of the porto caval collateral circulation, the concentration of fibrin(ogen) split products were also increased. For comparison, patients with pre- and posthepatic blockage were investigated, whose portal hypertension was not caused by liver cirrhosis. Besides a mild thrombopenia they only showed a secondary hyperfibrinolysis. The results, above all in the cases of liver cirrhosis, can be explained by pathophysiological mechanism: a decreased synthesis of clotting factors-a disturbed portal microcirculation with fibrin deposition-an impaired function of the liver RES.

Blood Coagulation Disorders↗
PubMed1972

Disordered blood coagulation in burned children receiving high molecular weight dextran.

Coagulation studies were performed on nine children with burns. Four of these children received treatment which included intravenous dextran; all four showed abnormalities of coagulation and two of them developed a bleeding state. No abnormalities of haemostasis were detected in the remaining five children who had comparable degrees of burns but whose treatment did not include intravenous dextran.

Blood Coagulation↗
PubMed1996

[Recommendations for initial diagnosis and therapy in acute blood coagulation disorders].

Acute disturbances of blood coagulation during operations and intensive therapy require quick and precise action in order to avoid life-threatening situations. This paper reports on a simple system for the diagnosis and therapy of acute disturbances of blood coagulation. In the initial phase of bleeding, determination of fibrin monomers, d-dimers, reptilase time, number of platelets and AT III enables diagnosis of disseminated intravascular coagulation (DIC), hyperfibrinolysis and consumption coagulopathy. Particular attention is paid to local hyperfibrinolysis, a relatively rare complication but of high diagnostic importance. After some remarks on the recommended clinical test parameters, the principles of the treatment of various coagulation disturbances are described. AT III is of special importance for the treatment of DIC, where as different opinions exist regarding the application of heparin. Aprotinin has long proved successful in the specific treatment of hyperfibrinolysis. Using clinical examples, the practicability of the recommended diagnostic and therapeutic measures is demonstrated.

Acute Disease↗